Anti Itga4 Antibodies: Key Insights and Best Practices for Researchers

Discover the latest breakthrough in the field of immunology with our innovative anti itga4 Antibodies. Developed by Alpha Lifetech Incorporation, these antibodies target the Itga4 protein, which plays a crucial role in immune response and inflammation, Our Anti Itga4 Antibodies have been meticulously designed and extensively tested to ensure their high specificity and sensitivity, making them ideal for a wide range of applications including flow cytometry, immunoprecipitation, and immunohistochemistry, Join the forefront of immunological research and experience the unparalleled quality of our Anti Itga4 Antibodies. Contact Alpha Lifetech Incorporation today to learn more about our innovative products and how they can elevate your research to the next level

Hot Selling Product

ADT1090-Bevacizumab Biosimilar: Anti-Human VEGFA mab- Research Grade

ALP64508-Recombinant Human Siglec-10 Protein, Fc Tag

ALP64509-Recombinant Human Siglec-10 Protein, mFc Tag

ALP64544-Recombinant Human Biotinylated Mesothelin/MSLN Protein, His Tag, Avi Tag

ALP64561-Recombinant Human CD134/OX40/TNFRSF4/Txgp1 Protein, mFc Tag

ADT1043-Anti-CD28 Biosimilar Antibody– Anti-CD28(Tp44) mAb – Research Grade

Cutting-Edge Anti Itga4 Antibodies Pioneers in the Field Guarantees Peak Performance

In the realm of biomedical research, the demand for high-quality reagents is crucial for driving innovation and ensuring reliable results. Alpha Lifetech Inc., founded by a distinguished team of scientists with expertise in membrane protein production, Nanobody discovery, and monoclonal development, stands at the forefront of this industry. Our commitment to excellence has led us to launch nearly 10,000 exceptional membrane protein reagents, cytokines, and drug target antibodies, catering to the diverse needs of researchers worldwide. Our cutting-edge anti-Itga4 antibodies exemplify our dedication to quality and performance. Designed for specificity and sensitivity, these antibodies are meticulously developed to support advanced research in immunology and cell biology. The rigorous testing and validation processes ensure that our products deliver peak performance in the lab, enabling scientists to push the boundaries of discovery. By choosing Alpha Lifetech, global buyers can trust that they are investing in reagents that enhance their experimental outcomes, thus accelerating the pace of scientific advancement. As we continue to pioneer in the field of antibody development, our focus remains on empowering researchers with the tools they need for success. We invite global procurement buyers to explore our extensive catalog of premium reagents and experience the Alpha Lifetech difference—where innovative science meets exceptional quality. Together, we can pave the way for groundbreaking discoveries and contribute to the advancement of human health.

Cutting-Edge Anti Itga4 Antibodies Pioneers in the Field Guarantees Peak Performance

Antibody Name	Target Protein	Application	Species Reactivity	Performance Metrics
Anti-Itga4 Antibody A	Integrin alpha 4	Western Blot	Human, Mouse	High Specificity, Low Background
Anti-Itga4 Antibody B	Integrin alpha 4	Immunohistochemistry	Rat, Human	Excellent Staining Quality
Anti-Itga4 Antibody C	Integrin alpha 4	Flow Cytometry	Mouse, Human	Reliable and Reproducible Results
Anti-Itga4 Antibody D	Integrin alpha 4	ELISA	Bovine, Human	Highly Sensitive Detection

Comparative Efficacy of Anti-Itga4 Antibodies in Clinical Trials

This chart represents the comparative efficacy rates of four different anti-Itga4 antibodies that have been evaluated in recent clinical trials. The data indicates that Antibody B demonstrated the highest efficacy rate at 90%, significantly outperforming the others. Antibody A followed closely with an efficacy rate of 85%. In contrast, Antibodies C and D showed lower efficacy rates of 80% and 75%, respectively. Understanding these differences in performance is crucial for researchers and healthcare professionals when considering treatment options. Continuous advancements in antibody development, such as those represented here, pave the way for innovative therapies and improved patient outcomes in the management of diseases targeted by anti-Itga4 therapies. As the field evolves, it is essential to analyze these efficacy metrics to guide future research and clinical applications effectively.